Announced Date: 2023-02-12 (February 12, 2023) Asset Name: SHR2554 (TLN-254) Licensor: Hengrui Pharmaceuticals Co. Ltd (China) … [China BD 2023] Hengrui and Treeline enters a 706 million USD license on EZH2 inhibitor SHR2554 (TLN-254)Read more
[China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatment
Announced Date: 2023-02-01 (February 1, 2023) Asset Name: CB06-036（CB06） Licensor: Shanghai Zhimeng Biopharma (China) Licensee (Buyer): … [China BD 2023] Zhimeng Biopharma and GSK enters a license on TLR8A CB06-036 (CB06) for HBV treatmentRead more
[China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI Fruquintinib
Announced Date: 2023-01-23 (January 23, 2023) Asset Name: Fruquintinib Licensor: HutchMed (China) Licensee (Buyer): Takeda (Japan) … [China BD 2023] HutchMed and Takeda enters a 1.13 billion USD License on VEGFR TKI FruquintinibRead more
[China BD deal 2022] Kelun-Biotech and Merck/MSD enters a 9.5 billion USD license on seven preclinical ADCs
Announced Date: 2022-12-22 (December 22, 2022) Asset: Seven investigational preclinical ADC for the treatment of cancer. … [China BD deal 2022] Kelun-Biotech and Merck/MSD enters a 9.5 billion USD license on seven preclinical ADCsRead more
[China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1/VEGF BsAbs Ivonescimab (AK112 / SMT112)
Announced Date: 2022-12-06 (December 06, 2022) Asset Name: Ivonescimab (AK112, SMT112) Licensor: Akeso Inc. (China) Licensee … [China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1/VEGF BsAbs Ivonescimab (AK112 / SMT112)Read more
[China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022
Drug Name: Dorzagliatin Drug Modality: Small Molecule Drug Target: GKA (Glucokinase Activator ) Developed By：Hua Medicine Approved Date: … [China FIC Drug] Global First In Class Glucokinase Activator Dorzagliatin (Oral Antidiabetic Drug) Approved by China NMPA in 2022Read more
[China BD 2022] Jemincare and Genentech (Roche) enters a 650 million USD license on AR degrader JMKX002992 (RG6537, GDC-2992)
Announced Date: 2022-08-05 (August 18, 2025) Asset Name: JMKX002992 (RG6537, GDC-2992) Licensor: Shanghai Jemincare Pharmaceutical (China) … [China BD 2022] Jemincare and Genentech (Roche) enters a 650 million USD license on AR degrader JMKX002992 (RG6537, GDC-2992)Read more
[China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on TROP2 ADC SKB-264
Announced Date: 2022-07-26 (July 26, 2022) Asset Name: SKB-264 (MK-2870) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun … [China BD deal 2022] Kelun-Biotech and MSD enters a 935 million USD license on TROP2 ADC SKB-264Read more
[China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar mAb Assets HLX11 and HLX14
Announced Date: 2022-06-13 ( June 13, 2022) Asset Name: Perjeta® (pertuzumab, HLX11) and Prolia®/Xgeva® (denosumab, HLX14). Licensor: Shanghai Henlius … [China BD 2022] Henlius and Organon enters a 471 billion USD license on two Biosimilar mAb Assets HLX11 and HLX14Read more
[China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on Claudin18.2 ADC SKB-315(MK-1200)
Announced Date: 2022-05-16 (May 16, 2022) Asset Name: SKB-315 (MK-1200) Licensor: Kelun-Biotech (subsidiary of Sichuan Kelun … [China BD deal 2022] Kelun-Biotech and MSD enters a 1.41 billion USD license on Claudin18.2 ADC SKB-315(MK-1200)Read more